BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries | ONC Stock NewsStockTitan·18 hours agoBGNE0.00%ONC+1.83%
Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)Tip Ranks·Aug 14 at 04:15 AMBGNE0.00%06160+3.18%
BOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160)Tip Ranks·Aug 9 at 09:35 AMBGNE0.00%06160+3.18%
CICC Raises BEONE MEDICINES TP to HKD266; 2Q Results BeatAASTOCKS News·Aug 6 at 11:21 PMBGNE0.00%06160+3.18%
BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updatesPUBT·Aug 5 at 08:16 AMONC+1.83%688235+1.34%
BeOne Medicines Posts Unaudited Q2 2026 Results and Cautions on Preliminary GuidanceTip Ranks·Aug 5 at 05:37 AMONC+1.83%BGNE0.00%
BeOne Medicines: Q2 2026 revenue up 30% to $1.7B, net income up 151%, driven by strong product sales and margin gainsQuartr·Aug 5 at 05:16 AMBGNE0.00%ONC+1.83%
